Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease(REAL-CAD).

Trial Profile

Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease(REAL-CAD).

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 May 2018

At a glance

  • Drugs Pitavastatin (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms REAL-CAD
  • Most Recent Events

    • 15 May 2018 Status changed from active, no longer recruiting to completed.
    • 08 May 2018 Primary endpoint of composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization has been met, accoring to results published in the Circulation.
    • 08 May 2018 Results published in the Circulation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top